Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.

doi:10.1001/jamaoncol.2022.2719

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.

JAMA oncology - 1 Sept 2022

Xu Jiachen, Liu Zheng, Bai Hua, Dong Guilan, Zhong Jia, Wan Rui, Zang Aiming, Li Xiaoling, Li Qingshan, Guo Jun, Du Nan, Zhong Diansheng, Huang Yan, Lv Qun, Zhang Jinghua, Zhao Yue, Gao Liming, Li Lin, Zhang Chunyi, Zhao Jun, Li Baolan, Liu Zhe, Yang Zhenlin, Ji Dong, Wang Tao, Duan Jianchun, Wang Zhijie, Wang Jie

Abstract excerpt

Importance: The inability to obtain a pathological diagnosis in a certain proportion of patients with clinically diagnosed advanced lung cancer impedes precision treatment in clinical practice. Objective: To evaluate the clinical outcome of first-line icotinib in patients with clinically diagnosed advanced lung cancer with unknown pathological status and positive epidermal growth factor receptor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Circulating Tumor DNA

Share to Crown Ethers

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 35862035
DOI: 10.1001/jamaoncol.2022.2719
PMCID: PMC9305594

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.PMID 35862035Read ↗

Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort.Semantic proximity Read ↗

Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis.Semantic proximity Read ↗

Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result.Semantic proximity Read ↗

Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review.Semantic proximity Read ↗

Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.Semantic proximity Read ↗

[Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma].Semantic proximity Read ↗

Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.Semantic proximity Read ↗

Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR- mutated metastatic Non-Small Cell Lung CancerSemantic proximity Read ↗

Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer.Semantic proximity Read ↗

Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.